Remove 2019 Remove Marketing Remove Safety
article thumbnail

A comment on the 2024 EWG Sunscreen Guide; Is EWG actively harming safe consumer sun protection?

The Eco Well Blog

Or are they putting these guides out as a fear marketing campaign to promote the EWG seal program (which makes them money)? But hopefully it gives you the gist of why it’s unreliable and why I’ve come to the conclusion that these guides are part of a greater marketing campaign by the EWG. market while tests are still being conducted.

article thumbnail

European Congress on Advanced Treatments and Technologies in Skin & Aesthetics

Online Laser Training

Dr Godfrey Town gave a talk on ‘ Update on Home-Use Devices: New Devices, Regulations & Safety ’ as an Invited Speaker at the new European Congress on Advanced Treatments and Technologies in Skin & Aesthetics (Skin-Med2019) annual conference held 5th to 8th December 2019 at the Holton Munich City Hotel in Germany.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

European Congress on Advanced Treatments and Technologies in Skin & Aesthetics

Online Laser Training

Dr Godfrey Town gave a talk on ‘ Update on Home-Use Devices: New Devices, Regulations & Safety ’ as an Invited Speaker at the new European Congress on Advanced Treatments and Technologies in Skin & Aesthetics (Skin-Med2019) annual conference held 5th to 8th December 2019 at the Holton Munich City Hotel in Germany.

article thumbnail

European Congress on Advanced Treatments and Technologies in Skin & Aesthetics

Online Laser Training

Dr Godfrey Town gave a talk on ‘ Update on Home-Use Devices: New Devices, Regulations & Safety ’ as an Invited Speaker at the new European Congress on Advanced Treatments and Technologies in Skin & Aesthetics (Skin-Med2019) annual conference held 5th to 8th December 2019 at the Holton Munich City Hotel in Germany.

article thumbnail

FDA, EMA Accept Galderma’s BLA for Nemolizumab for PN and AD

The Dermatology Digest

In addition, the European Medicines Agency has also accepted the Marketing Authorization Applications for nemolizumab in prurigo nodularis and atopic dermatitis. The European Medicines Agency has also accepted Galderma’s Marketing Authorization Applications for nemolizumab in both prurigo nodularis and atopic dermatitis.

article thumbnail

FDA Approves Galderma’s IL-31 Blocker in PN

The Dermatology Digest

Nemolizumab was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis.

article thumbnail

Nemolizumab Update: Galderma’s IL-31 Blocker Continues to Wow in PN, AD

The Dermatology Digest

In addition, the European Medicines Agency has also accepted the Marketing Authorization Applications for nemolizumab in prurigo nodularis and atopic dermatitis. No new safety signals were observed in this trial. The FDA has granted nemolizumab Priority Review for prurigo nodularis.